86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details

臨床試験数 : 1,205 /  薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

  
4 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2010-024585-22-DE
(EUCTR)		01/12/201617/08/2016What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency? - Ferinject® for iron deficiency in IPAH patients Idiopathic or familial pulmonary arterial hypertension
MedDRA version: 19.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]		Trade Name: Ferinject
Product Name: Ferinject
INN or Proposed INN: FERRIC CARBOXYMALTOSE		Imperial College Academic Healthsciences CentreNULLNot RecruitingFemale: yes
Male: yes		60Phase 2Germany;United Kingdom
2NCT01847352
(ClinicalTrials.gov)		February 20131/5/2013Iron Status and Hypoxic Pulmonary Vascular ResponsesEffect of Endogenous Iron Status on Hypoxic Pulmonary Vascular Responses and Their Attenuation by Intravenous IronLung Hypoxia;Pulmonary Arterial Hypertension;Iron DeficiencyDrug: Intravenous administration of ferric carboxymaltose;Other: Subacute hypoxic exposuresUniversity of OxfordNational Institute for Health Research, United Kingdom;British Heart FoundationCompleted18 YearsN/ABoth31N/AUnited Kingdom
3EUCTR2010-024585-22-GB
(EUCTR)		25/03/201125/02/2011What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency? - Ferinject® for iron deficiency in IPAH patients Idiopathic or familial pulmonary arterial hypertension
MedDRA version: 18.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]		Trade Name: Ferinject
Product Name: Ferinject
INN or Proposed INN: Ferric carboxymaltose		Imperial College Academic Healthsciences CentreNULLNot Recruiting Female: yes
Male: yes		 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noGermany;United Kingdom
4EUCTR2010-023233-30-NL
(EUCTR)		13/12/201006/10/2010‘Intravenous iron treatment in iron deficient patients with pulmonary arterialhypertension' - Treating iron deficiency in PAH‘Intravenous iron treatment in iron deficient patients with pulmonary arterialhypertension' - Treating iron deficiency in PAH Objective: To evaluate the effects of intravenous iron suppletion in iron deficient IPAH patients.Study design: Intervention studyStudy population: Patients with idiopathic pulmonary arterial hypertension (IPAH) and iron deficiencyIntervention:Patients receive a weekly iron bolus infusion until iron levels are restored (correction phase). Then a maintenance dose is given once per month (maintenance phase) until the endpoint after 20 weeks.
MedDRA version: 12.1;Level: LLT;Classification code 10064909;Term: Idiopathic (IPAH)		Trade Name: Ferinject
Product Name: Ferric carboxymaltose
Product Code: RVG 33865		VU university medical centerNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		30Netherlands